Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.25
CNMD's Cash to Debt is ranked lower than
55% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. CNMD: 0.25 )
CNMD' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 0.25

Equity to Asset 0.56
CNMD's Equity to Asset is ranked higher than
59% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. CNMD: 0.56 )
CNMD' s 10-Year Equity to Asset Range
Min: 0.29   Max: 0.93
Current: 0.56

0.29
0.93
Interest Coverage 10.07
CNMD's Interest Coverage is ranked higher than
50% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 205.72 vs. CNMD: 10.07 )
CNMD' s 10-Year Interest Coverage Range
Min: 1.24   Max: 128
Current: 10.07

1.24
128
F-Score: 6
Z-Score: 3.07
M-Score: -2.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 7.41
CNMD's Operating margin (%) is ranked higher than
74% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. CNMD: 7.41 )
CNMD' s 10-Year Operating margin (%) Range
Min: -0.71   Max: 20.38
Current: 7.41

-0.71
20.38
Net-margin (%) 4.71
CNMD's Net-margin (%) is ranked higher than
72% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. CNMD: 4.71 )
CNMD' s 10-Year Net-margin (%) Range
Min: -5.13   Max: 12.98
Current: 4.71

-5.13
12.98
ROE (%) 5.93
CNMD's ROE (%) is ranked higher than
72% of the 365 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. CNMD: 5.93 )
CNMD' s 10-Year ROE (%) Range
Min: -4.36   Max: 14.53
Current: 5.93

-4.36
14.53
ROA (%) 3.30
CNMD's ROA (%) is ranked higher than
72% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. CNMD: 3.30 )
CNMD' s 10-Year ROA (%) Range
Min: -1.45   Max: 9.58
Current: 3.3

-1.45
9.58
ROC (Joel Greenblatt) (%) 16.31
CNMD's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 12.55 vs. CNMD: 16.31 )
CNMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1.58   Max: 38.07
Current: 16.31

-1.58
38.07
Revenue Growth (%) 3.20
CNMD's Revenue Growth (%) is ranked higher than
68% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. CNMD: 3.20 )
CNMD' s 10-Year Revenue Growth (%) Range
Min: -0.1   Max: 40.8
Current: 3.2

-0.1
40.8
EBITDA Growth (%) 5.80
CNMD's EBITDA Growth (%) is ranked higher than
82% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. CNMD: 5.80 )
CNMD' s 10-Year EBITDA Growth (%) Range
Min: -35.8   Max: 43.5
Current: 5.8

-35.8
43.5
EPS Growth (%) 6.80
CNMD's EPS Growth (%) is ranked higher than
80% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. CNMD: 6.80 )
CNMD' s 10-Year EPS Growth (%) Range
Min: -72   Max: 49.7
Current: 6.8

-72
49.7
» CNMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

CNMD Guru Trades in Q1 2013

Jim Simons 59,181 sh (+124.33%)
Ken Fisher 91,400 sh (+39.12%)
John Keeley 44,670 sh (+27.74%)
Joel Greenblatt 83,156 sh (+2.88%)
Mario Gabelli 93,900 sh (-0.53%)
Chuck Royce 82,200 sh (-1.32%)
Paul Tudor Jones 8,500 sh (-23.42%)
» More
Q2 2013

CNMD Guru Trades in Q2 2013

Paul Tudor Jones 27,800 sh (+227.06%)
Jim Simons 98,681 sh (+66.74%)
John Keeley 63,970 sh (+43.21%)
Ken Fisher 91,400 sh (unchged)
Mario Gabelli 93,900 sh (unchged)
Chuck Royce 82,200 sh (unchged)
Joel Greenblatt 48,778 sh (-41.34%)
» More
Q3 2013

CNMD Guru Trades in Q3 2013

John Keeley 71,770 sh (+12.19%)
Chuck Royce 82,200 sh (unchged)
Ken Fisher 91,400 sh (unchged)
Mario Gabelli 93,900 sh (unchged)
Jim Simons 74,181 sh (-24.83%)
Paul Tudor Jones 11,100 sh (-60.07%)
Joel Greenblatt 19,019 sh (-61.01%)
» More
Q4 2013

CNMD Guru Trades in Q4 2013

Chuck Royce 82,200 sh (unchged)
Jim Simons Sold Out
Joel Greenblatt Sold Out
Mario Gabelli 93,200 sh (-0.75%)
Ken Fisher 74,200 sh (-18.82%)
John Keeley 54,620 sh (-23.9%)
Paul Tudor Jones 7,300 sh (-34.23%)
» More
» Details

Insider Trades

Latest Guru Trades with CNMD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Sold Out 0.02%$33.25 - $42.48 $ 47.6525%0
John Keeley 2013-12-31 Reduce -23.9%0.01%$33.25 - $42.48 $ 47.6525%54620
Joel Greenblatt 2013-09-30 Reduce -61.01%0.04%$31.07 - $33.76 $ 47.6546%19019
Joel Greenblatt 2013-06-30 Reduce -41.34%0.06%$30.42 - $34.04 $ 47.6547%48778
John Keeley 2013-06-30 Add 43.21%0.01%$30.42 - $34.04 $ 47.6547%63970
John Keeley 2013-03-31 Add 27.74%0.01%$27.95 - $34.29 $ 47.6557%44670
John Keeley 2012-12-31 New Buy0.02%$25.71 - $29.33 $ 47.6573%34970
Joel Greenblatt 2012-03-31 Add 39.72%0.04%$26.44 - $30.47 $ 47.6577%57083
Joel Greenblatt 2011-12-31 Add 53.81%0.05%$21.72 - $27.83 $ 47.6586%40854
Joel Greenblatt 2011-09-30 Add 38.04%0.03%$20.81 - $29.38 $ 47.6594%26561
Joel Greenblatt 2011-06-30 New Buy0.08%$25.99 - $29 $ 47.6573%19242
Mario Gabelli 2011-03-31 Reduce -51.25%0.02%$25.33 - $27.47 $ 47.6581%95800
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 37.40
CNMD's P/E(ttm) is ranked lower than
51% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 26.70 vs. CNMD: 37.40 )
CNMD' s 10-Year P/E(ttm) Range
Min: 9.88   Max: 755.25
Current: 37.4

9.88
755.25
P/B 2.40
CNMD's P/B is ranked higher than
69% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. CNMD: 2.40 )
CNMD' s 10-Year P/B Range
Min: 0.61   Max: 2.4
Current: 2.4

0.61
2.4
P/S 1.80
CNMD's P/S is ranked higher than
71% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. CNMD: 1.80 )
CNMD' s 10-Year P/S Range
Min: 0.48   Max: 1.8
Current: 1.8

0.48
1.8
PFCF 21.50
CNMD's PFCF is ranked higher than
74% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 27.48 vs. CNMD: 21.50 )
CNMD' s 10-Year PFCF Range
Min: 7.44   Max: 2046
Current: 21.5

7.44
2046
EV-to-EBIT 26.30
CNMD's EV-to-EBIT is ranked lower than
52% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 20.91 vs. CNMD: 26.30 )
CNMD' s 10-Year EV-to-EBIT Range
Min: 7.6   Max: 153.1
Current: 26.3

7.6
153.1
PEG 2.80
CNMD's PEG is ranked higher than
65% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. CNMD: 2.80 )
CNMD' s 10-Year PEG Range
Min: 1.23   Max: 240.33
Current: 2.8

1.23
240.33
Shiller P/E 49.60
CNMD's Shiller P/E is ranked lower than
57% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 27.00 vs. CNMD: 49.60 )
CNMD' s 10-Year Shiller P/E Range
Min: 11.93   Max: 50.1
Current: 49.6

11.93
50.1

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.50
CNMD's Dividend Yield is ranked higher than
64% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.28 vs. CNMD: 1.50 )
CNMD' s 10-Year Dividend Yield Range
Min: 0.5   Max: 2.22
Current: 1.5

0.5
2.22
Dividend Payout 0.51
CNMD's Dividend Payout is ranked lower than
55% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 0.35 vs. CNMD: 0.51 )
CNMD' s 10-Year Dividend Payout Range
Min: 0.43   Max: 0.51
Current: 0.51

0.43
0.51
Yield on cost (5-Year) 1.50
CNMD's Yield on cost (5-Year) is ranked higher than
58% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 1.39 vs. CNMD: 1.50 )
CNMD' s 10-Year Yield on cost (5-Year) Range
Min: 0.5   Max: 2.22
Current: 1.5

0.5
2.22
Share Buyback Rate 0.90
CNMD's Share Buyback Rate is ranked higher than
91% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: -1.30 vs. CNMD: 0.90 )
CNMD' s 10-Year Share Buyback Rate Range
Min: 1.6   Max: -16.1
Current: 0.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 34.30
CNMD's Price/Tangible Book is ranked lower than
91% of the 328 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. CNMD: 34.30 )
CNMD' s 10-Year Price/Tangible Book Range
Min: 3.39   Max: 32.5
Current: 34.3

3.39
32.5
Price/DCF (Projected) 1.50
CNMD's Price/DCF (Projected) is ranked higher than
76% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. CNMD: 1.50 )
CNMD' s 10-Year Price/DCF (Projected) Range
Min: 0.78   Max: 1.3
Current: 1.5

0.78
1.3
Price/Median PS Value 1.60
CNMD's Price/Median PS Value is ranked lower than
62% of the 338 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. CNMD: 1.60 )
CNMD' s 10-Year Price/Median PS Value Range
Min: 0.61   Max: 2.64
Current: 1.6

0.61
2.64
Price/Peter Lynch Fair Value 6.60
CNMD's Price/Peter Lynch Fair Value is ranked lower than
80% of the 59 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. CNMD: 6.60 )
CNMD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.55   Max: 7.78
Current: 6.6

0.55
7.78
Price/Graham Number 7.50
CNMD's Price/Graham Number is ranked lower than
81% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. CNMD: 7.50 )
CNMD' s 10-Year Price/Graham Number Range
Min: 1.66   Max: 14.59
Current: 7.5

1.66
14.59
Earnings Yield (Greenblatt) 3.80
CNMD's Earnings Yield (Greenblatt) is ranked higher than
58% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. CNMD: 3.80 )
CNMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 13.1
Current: 3.8

0.7
13.1
Forward Rate of Return (Yacktman) 8.38
CNMD's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. CNMD: 8.38 )
CNMD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -16.1   Max: 19.9
Current: 8.38

-16.1
19.9

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:EC8.Germany
Conmed Corporation was incorporated under the laws of the State of New York in 1970. It is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and monitoring. The Company's products serve the clinical areas of arthroscopy, powered surgical instruments, electrosurgery and cardiac monitoring disposables, endosurgery and endoscopic technologies. They are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. The Company conducts its business through five principal operating segments: CONMED Endoscopic Technologies, CONMED Endosurgery, CONMED Electrosurgery, CONMED Linvatec and CONMED Patient Care. CONMED Endosurgery, CONMED Electrosurgery and CONMED Linvatec segments product offerings include a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic procedures, electrosurgical generators and related surgical instruments, arthroscopic instrumentation for use in orthopedic surgery and small bone, large bone and specialty powered surgical instruments. CONMED Patient Care segment product offerings include a line of vital signs and cardiac monitoring products including pulse oximetry equipment & sensors, ECG electrodes and cables, cardiac defibrillation & pacing pads and blood pressure cuffs. It also offers a complete line of reusable surgical patient positioners and suction instruments & tubing for use in the operating room, as well as a line of IV products. CONMED Endoscopic Technologies segment product offerings include a comprehensive line of minimally invasive endoscopic diagnostic and therapeutic instruments used in procedures which require examination of the digestive tract. The Company's products are distributed domestically directly to more than 6,000 hospitals and other healthcare institutions as well as through medical specialty distributors and surgeons. The Company manufacture substantially all of its products and assemble them from components, many of which it produce. The Company uses numerous raw materials and components in the design, development and manufacturing of its products. The Company's competitors are Smith & Nephew, plc, Arthrex, Inc., Stryker Corporation, ArthroCare Corporation, Johnson & Johnson: DePuy Mitek, Inc., Biomet, Inc., Medtronic, Inc. Midas Rex and Xomed divisions, Synvasive Technology, Inc., Synthes, Inc., MicroAire Surgical Instruments, LLC, 3M Company, ERBE Elektromedizin GmbH, Covidien Ltd, Johnson & Johnson: Ethicon Endo-Surgery, Inc., Boston Scientific Corporation - Endoscopy, Wilson-Cook Medical, Inc., Olympus America, Inc., and U.S. Endoscopy. The Company's operations are subject to a number of environmental laws and regulations governing, among other things, air emissions, wastewater discharges, the use, handling and disposal of hazardous substances and wastes, soil and groundwater remediation and employee hea

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide